TrialDrugs in R&D2019

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.

Andreas Muehler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.